Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a report issued on Thursday, Benzinga reports. They currently have a $17.00 target price on the biopharmaceutical company’s stock.
Palatin Technologies Price Performance
PTN opened at $1.87 on Thursday. The company has a market cap of $30.10 million, a price-to-earnings ratio of -0.75 and a beta of 0.93. Palatin Technologies has a one year low of $1.43 and a one year high of $5.65.
Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report) last released its quarterly earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.03). Palatin Technologies had a negative net margin of 445.12% and a negative return on equity of 583.06%. During the same period in the prior year, the business posted ($0.63) EPS. Equities research analysts forecast that Palatin Technologies will post -2.41 EPS for the current fiscal year.
Institutional Inflows and Outflows
Palatin Technologies Company Profile
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.
Further Reading
- Five stocks we like better than Palatin Technologies
- How to Calculate Stock Profit
- Sarepta Therapeutics Stock Soars on FDA Approval
- How to Use the MarketBeat Dividend Calculator
- CarMax: A Market Melt-Up Waiting to Happen for this Stock
- Manufacturing Stocks Investing
- 3 Solar Stocks to Watch that are Building the Green Energy Future
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.